Adimab inks deals with Lilly, Genentech and HGS

Lebanon, NH-based Adimab has added some noteworthy players to its long list of partners trying out its antibody development technology. The 2010 Fierce 15 company announced today that Eli Lilly, Genentech, and Human Genome Sciences have all inked new collaboration deals. "As more companies develop therapeutic leads against the same validated disease targets, leading Pharma companies are actively seeking out technologies that give them a meaningful advantage and Adimab's deal flow speaks for itself," said Tillman Gerngross, Adimab's CEO and co-founder. "In this highly competitive environment, having access to the best technology becomes essential, not optional. Our ability to provide high quality leads in a matter of months is driving the demand for our technology." Adimab release

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.